Vriens BEPJ, et al. - The INTENS study determined whether or not delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improved outcome of breast cancer patients. With respect to the pathologic complete response (pCR) rate, there weere no differences between the two treatment arms, but the sequentially-delivered chemotherapy was shown to be superior to triplet combination chemotherapy in terms of survival, despite a lower cumulative dose per agent.